GlassScriptPhysician profile
Jim Hussey
NPI 1417035692
$7,938.29
in general payments reported to CMS, 2019-2025
31 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,744 · 2020: $1,353 · 2021: $1,261 · 2022: $1,015 · 2023: $1,557 · 2024: $900 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,553.20 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,117.04 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,218.50 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $871.12 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $751.84 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $513.05 | 2019-2023 | |
| Amarin Pharma, INC. | $405.20 | 2019-2021 | |
| Glaxosmithkline, LLC. | $265.96 | 2021-2024 | Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $196.03 | 2020-2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $195.68 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.21 | 2019-2023 | Jardiance, Synjardy |
| Abbvie INC. | $160.73 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $159.64 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $159.17 | 2020-2022 | |
| Eisai INC. | $147.31 | 2020-2021 | |
| Noven Pharmaceuticals, INC. | $96.19 | 2023 | Xelstrym |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $81.75 | 2019-2020 | |
| Allergan, INC. | $64.58 | 2019-2020 | |
| Corium, LLC | $44.23 | 2022 | |
| Clarus Therapeutics INC. | $42.71 | 2021 | |
| Adlon Therapeutics L.P. | $39.84 | 2020-2021 | |
| Pfizer INC. | $36.08 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $27.53 | 2019 | |
| Esperion Therapeutics, INC. | $23.46 | 2020 | |
| Edwards Lifesciences Corporation | $20.63 | 2022 | |
| Lundbeck LLC | $18.32 | 2022 | |
| Aytu Biopharma, INC. | $18.04 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.32 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.02 | 2019 | |
| Nabriva Therapeutics, Plc | $16.01 | 2022 | |
| Shire North American Group INC | $15.30 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Hussey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.